Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Vera Therapeutics, Inc.
VERA
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.1B
$40.21
▼ -5.74%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$19.07 - $56.05
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 80.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-in-class or best-in-class potential for atacicept in IgAN treatment
- Subcutaneous self-administration route improving patient convenience
- Focused pipeline targeting high-unmet-need immunological diseases
- Experienced management team in immunology and gene therapy
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Positive Phase IIb clinical trial data for atacicept could drive regulatory approval pathway
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+4.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying VERA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 7, 2026
Reported EPS of -$1.69 vs -$1.33 consensus (-27.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-27.2%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
8 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$90.00
▲ +123.8% vs $40.21
Latest: Goldman Sachs · $90.00 · Jun 2, 2026
3 analysts covering